Octoplus extends drug delivery contract with Top-5 pharma company
Will combine product candidate with Octoplus PolyActive drug delivery technology
OctoPlus, a provider of drug formulation and clinical scale manufacturing services, has extended a drug delivery technology evaluation contract with a top-5 global pharmaceutical company.
The Amsterdam-based firm carried out feasibility work for previous compounds of this client in 2009 and 2010 and those studies have been successful. Pre-clinical studies performed with the prototype controlled release formulation were also successful.
Under the new contract, Octoplus will develop a controlled release formulation that combines the client's optimised product candidate with its proprietary PolyActive drug delivery technology.
If the project is successful, the contract may progress to a full process development and manufacturing contract, and a licensing agreement.